UK to be first to clear Pfizer-BioNTech Covid vaccine likely by next week

British doctors were put on standby for a possible rollout before Christmas.
The U.K. is poised to become the first country to approve Pfizer Inc. and BioNTech SE’s Covid-19 vaccine, ahead of a long line of countries waiting for protection from the coronavirus.

Clearance is possible as soon as early next week, according to a person familiar with the situation, who asked not to be identified because the process is confidential.

The U.K. had long signaled it would move fast on any promising vaccine candidate. Russia and China have cleared vaccines for general use, but they’re unlikely to be adopted in the U.S. and Europe.

British doctors were put on standby for a possible rollout before Christmas. The government invoked a special rule allowing the U.K. drug regulator to bypass its European Union counterpart as the country prepares for the Brexit transition period to conclude at the end of this year. And the U.K.’s Medicines and Healthcare Products Regulatory Agency started its own accelerated review.

Earlier this week, the MHRA said it had the data it needed to assess whether the Pfizer vaccine meets required standards and would “make a decision in the shortest time possible, without compromising the thoroughness of our review.” The shot was 95% effective in a clinical trial of almost 44,000 people, with no significant safety problems so far.

On Saturday, an MHRA spokesperson declined to comment. A BioNTech representative didn’t immediately have a comment. Pfizer said in a statement that it doesn’t speculate on how long the review process will last or how it will end.

Vaccine Minister

The first injections could take place from Dec. 7, the Financial Times reported earlier.

The news that the U.K. could approve a vaccine comes as Nadhim Zahawi, a junior minister for the Department of Business, was appointed as minister overseeing the rollout of Covid-19 vaccines.

The U.K. has ordered enough doses of the two-shot Pfizer-BioNTech vaccine to immunize 20 million people, though that volume almost certainly won’t be available right away. The companies also have deals to supply hundreds of millions of shots to Europe, the U.S., Japan and elsewhere.

The Pfizer-BioNTech shot has raced to the head of the line after delays to trials of a vaccine from AstraZeneca Plc and the University of Oxford, which has also shown some promising signs in preliminary results from broad studies. Another one, from Moderna Inc., has also demonstrated effectiveness in late-stage trials.

According to the U.K. Press Association late Saturday, the government has secured another 2 million doses of Moderna’s vaccine, talking its total to 7 million.

UK secures 2 mn more doses of Moderna vaccine

Britain has secured two million doses of Moderna’s Covid-19 vaccine candidate, to be available in Europe as early as the spring, the government said on Sunday, in addition to the 5 million doses it secured from the US company two weeks ago. Britain now has access to enough doses of Moderna's vaccine candidate for around 3.5 million people. Overall, it has access to 357 million doses of vaccines.

Reuters



Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.

We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Business Standard is now on Telegram.
For insightful reports and views on business, markets, politics and other issues, subscribe to our official Telegram channel